There is significant evidence that the accumulation of various genetic and epigenetic abnormalities, in addition to the BCR/ABL1 oncoprotein, influences disease progression, treatment response, and overall clinical prognosis in CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.